Familial adenomatous polyposis
Conditions
Interventions
2x colonoscopy with biopsies taken.
Treatment with MPA 10 mg/day for 4 months
Sponsors
afdeling maag darm en leverziekten LUMC
Eligibility
Inclusion criteria
Inclusion criteria: 1. Females > 14 years of age 2. Established FAP, confirmed by prior colonoscopy 3. Patients must be able to adhere to the study visits and protocol requirements 4. Patients must be able to give written informed consent. In case of a minor, parents/legal representative must be able to give a written consent. The consent must be obtained prior to any screening procedures
Exclusion criteria
Exclusion criteria: 1. Females before menarche 2. Prior progestin use in the past year 3. Change in the use of NSAIDs at least 3 month prior to the study 4. Allergic reaction on MPA during previous use 5. Female patients who are pregnant or breast-feeding. 6. Prior thromboflebitis or thromboembolism. 7. Previous or current serious cardiac or cerebrovascular condition. Like thromboflebitis or thromboembolism, severe hypertension, severe liverfunction disorders. A history of jaundice, herpes gestationis non-explained vaginal bleeding or deterioration of otosclerosis during pregnancy or use of female hormones. 8. Patients with fertility wish for the study period 9. Not available for follow-up assessment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in polyp burden | — |
Secondary
| Measure | Time frame |
|---|---|
| Biological response in the target tissue (colon) | — |
Contacts
Public ContactJarom Heijmans
Leiden University Medical Center (LUMC) Department of Gastroenterology and Hepatology
Outcome results
None listed